TokenPost·
Vir Biotechnology's Hepatitis Delta Combination Meets Phase 3 Goal
At week 48, 44% of treated patients met the trial’s combined primary endpoint. No patients assigned to delayed treatment had met it at week 12.
More news
- TokenPostMurphy Sees Bitcoin Recovery Case in Narrowing Indicator Troughs
- Crypto BriefingGalaxy’s Max Bareiss says DeFi is built for agentic trading
- The BlockPrediction market broker River Markets registers affiliate as CFTC futures commission merchant
- Crypto BriefingBNB Smart Chain tops rankings with 4.86M active addresses in 24 hours
- TokenPostOutgoing Binance CFO Kaiser Ng Plans Asset Tokenization Projects
- CryptopolitanDisney and Adobe sign deal for custom AI models